However, GSK-J4 alleviated DSS-induced and YAPIEC−/−-aggravated acute colitis by suppressing the proinflammatory response with reduced levels of chemokines and ameliorating intestinal injury by reversing Occludin and E-cadherin expression. The gene discussed is OCLN; the disease is colitis.